1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/32083
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMehta S.R.en
dc.contributor.authorEikelboom J.W.en
dc.contributor.authorTran H.en
dc.date.accessioned2021-05-14T10:51:41Zen
dc.date.available2021-05-14T10:51:41Zen
dc.date.copyright2006en
dc.date.created20070326en
dc.date.issued2012-10-16en
dc.identifier.citationVascular Health and Risk Management. 2 (4) (pp 379-387), 2006. Date of Publication: 2006.en
dc.identifier.issn1176-6344en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/32083en
dc.description.abstractThe pathogenesis of ST-elevation myocardial infarction (STEMI) involves plaque disruption, platelet aggregation and intracoronary artery thrombus formation. Aspirin is the cornerstone of antiplatelet therapy in patients with STEMI, reducing the risk of recurrent myocardial infarction or death during the acute phase and long term by about one-quarter. Recent large randomized trials have demonstrated that the addition of clopidogrel to aspirin reduces the risk of major ischemic events by up to a further one-third in patients with STEMI treated with fibrinolytic therapy and undergoing percutaneous coronary intervention, with no significant increase in bleeding. Thus, dual antiplatelet therapy with the combination of elopidogrel and aspirin is becoming the new standard of care for the management of patients with STEMI. © 2006 Dove Medical Press Limited. All rights reserved.en
dc.languageenen
dc.languageEnglishen
dc.publisherDOVE Medical Press Ltd. (PO Box 300-008, Albany, Auckland, New Zealand)en
dc.titleClinical update on the therapeutic use of clopidogrel: Treatment of acute ST-segment elevation myocardial infarction (STEMI).en
dc.typeReviewen
dc.type.studyortrialRandomised controlled trial-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.2147/vhrm.2006.2.4.379en
dc.publisher.placeNew Zealanden
dc.identifier.pubmedid17323592 [http://www.ncbi.nlm.nih.gov/pubmed/?term=17323592]en
dc.identifier.source46237363en
dc.identifier.institution(Tran) Department of Clinical Haematology, Monash Medical Centre, Monash, VIC, Australia (Mehta, Eikelboom) Department of Medicine, McMaster University, 237 Barton St East, Hamilton, ON L9K 1H8, Canadaen
dc.description.addressJ.W. Eikelboom, Department of Medicine, Hamilton General Hospital (HGH), McMaster Clinic, 237 Barton St East, Hamilton, ON L9K 1H8, Canada. E-mail: eikelbj@mcmaster.caen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2012 Elsevier B.V., All rights reserved.en
dc.subect.keywordsAcute coronary syndrome Antiplatelet drugs Clopidogrel Myocardial infarctionen
dc.identifier.authoremailEikelboom J.W.; eikelbj@mcmaster.caen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeReview-
crisitem.author.deptHaematology-
Appears in Collections:Articles
Show simple item record

Page view(s)

70
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.